160 related articles for article (PubMed ID: 38206570)
1. Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.
Kaistha BP; Kar G; Dannhorn A; Watkins A; Opoku-Ansah G; Ilieva K; Mullins S; Anderton J; Galvani E; Garcon F; Lapointe JM; Brown L; Hair J; Slidel T; Luheshi N; Ryan K; Hardaker E; Dovedi S; Kumar R; Wilkinson RW; Hammond SA; Eyles J
Cancer Biol Ther; 2024 Dec; 25(1):2296048. PubMed ID: 38206570
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR.
Ploeg EM; Samplonius DF; Xiong X; Ke X; Hendriks MAJM; Britsch I; van Wijngaarden AP; Zhang H; Helfrich W
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37734877
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Combination Strategies for the A
Voronova V; Peskov K; Kosinsky Y; Helmlinger G; Chu L; Borodovsky A; Woessner R; Sachsenmeier K; Shao W; Kumar R; Pouliot G; Merchant M; Kimko H; Mugundu G
Front Immunol; 2021; 12():617316. PubMed ID: 33737925
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
5. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
6. Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model.
Wu Y; Deng Z; Wang H; Ma W; Zhou C; Zhang S
BMC Immunol; 2016 Sep; 17(1):29. PubMed ID: 27645787
[TBL] [Abstract][Full Text] [Related]
7. CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.
Ye J; Gavras NW; Keeley DC; Hughson AL; Hannon G; Vrooman TG; Lesch ML; Johnston CJ; Lord EM; Belt BA; Linehan DC; Eyles J; Gerber SA
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142292
[TBL] [Abstract][Full Text] [Related]
8. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade.
Kwong TT; Wong CH; Zhou JY; Cheng ASL; Sung JJY; Chan AWH; Chan SL
JHEP Rep; 2021 Apr; 3(2):100224. PubMed ID: 33604533
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.
Kurago Z; Guo G; Shi H; Bollag RJ; Groves MW; Byrd JK; Cui Y
Front Immunol; 2023; 14():1212209. PubMed ID: 37435071
[TBL] [Abstract][Full Text] [Related]
11. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
[TBL] [Abstract][Full Text] [Related]
12. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer.
Kim M; Min YK; Jang J; Park H; Lee S; Lee CH
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253638
[TBL] [Abstract][Full Text] [Related]
13. Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy.
Yuan CS; Teng Z; Yang S; He Z; Meng LY; Chen XG; Liu Y
J Control Release; 2022 Nov; 351():255-271. PubMed ID: 36165836
[TBL] [Abstract][Full Text] [Related]
14. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.
Beavis PA; Milenkovski N; Henderson MA; John LB; Allard B; Loi S; Kershaw MH; Stagg J; Darcy PK
Cancer Immunol Res; 2015 May; 3(5):506-17. PubMed ID: 25672397
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.
Principe N; Aston WJ; Hope DE; Tilsed CM; Fisher SA; Boon L; Dick IM; Chin WL; McDonnell AM; Nowak AK; Lake RA; Chee J; Lesterhuis WJ
Front Immunol; 2022; 13():872295. PubMed ID: 35634282
[TBL] [Abstract][Full Text] [Related]
16. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
17. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.
Zhang T; Liu H; Jiao L; Zhang Z; He J; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Zhang H; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365585
[TBL] [Abstract][Full Text] [Related]
18. Dual role of CD73 as a signaling molecule and adenosine-generating enzyme in colorectal cancer progression and immune evasion.
Lian W; Jiang D; Lin W; Jiang M; Zhang Y; Wang H; Zhao L
Int J Biol Sci; 2024; 20(1):137-151. PubMed ID: 38164172
[TBL] [Abstract][Full Text] [Related]
19. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
20. A Novel CD73 Inhibitor SHR170008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-1 Blockade in a Mouse Model of Breast Cancer.
Liu S; Li D; Liu J; Wang H; Horecny I; Shen R; Zhang R; Wu H; Hu Q; Zhao P; Zhang F; Yan Y; Feng J; Zhuang L; Li J; Zhang L; Tao W
Onco Targets Ther; 2021; 14():4561-4574. PubMed ID: 34466002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]